Sharing my story helps raise awareness about pulmonary fibrosis
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.| Pulmonary Fibrosis News
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.| Pulmonary Fibrosis News
Trevi Therapeutics plans to launch two Phase 2 clinical trials testing Haduvio for chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with chronic cough.| Pulmonary Fibrosis News
A Phase 2b clinical trial testing Haduvio for IPF cough reached 75% of targeted enrollment but is still recruiting patients in 10 countries.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing trial.| Pulmonary Fibrosis News
Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.| Pulmonary Fibrosis News
Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.| Pulmonary Fibrosis News
There are more immune NK T-cells in the lungs of people with idiopathic pulmonary fibrosis than in healthy people, research shows| Pulmonary Fibrosis News
Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
While columnist Sam Kirton's quality of life improved after his lung transplant, the healing journey hasn't been easy, he says.| Pulmonary Fibrosis News
Learn more about the signs, symptoms and complications associated with the debilitating respiratory disease pulmonary fibrosis.| Pulmonary Fibrosis News
Learn more about the tests and examinations used to reach a diagnosis of pulmonary fibrosis, which is characterized by scarring in the lungs.| Pulmonary Fibrosis News
Read about the different factors that can cause pulmonary fibrosis.| Pulmonary Fibrosis News
Learn more about Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).| Pulmonary Fibrosis News
Learn about familial pulmonary fibrosis, a rare form of pulmonary fibrosis, including its symptoms, diagnosis, risk factors, and treatment.| Pulmonary Fibrosis News
Esbriet (pirfenidone) is an oral treatment that has been approved by the U.S. Food and Drug Administration for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.| Pulmonary Fibrosis News
During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News
